CY1123826T1 - Κρυσταλλικη μορφη 6 - [(4r) -4-μεθυλο-1,2-διοξειδο-1,2,6-θειαδιαζιναν-2-υλ]ισοκινολινο-1-καρβονιτριλιου - Google Patents
Κρυσταλλικη μορφη 6 - [(4r) -4-μεθυλο-1,2-διοξειδο-1,2,6-θειαδιαζιναν-2-υλ]ισοκινολινο-1-καρβονιτριλιουInfo
- Publication number
- CY1123826T1 CY1123826T1 CY20211100138T CY211100138T CY1123826T1 CY 1123826 T1 CY1123826 T1 CY 1123826T1 CY 20211100138 T CY20211100138 T CY 20211100138T CY 211100138 T CY211100138 T CY 211100138T CY 1123826 T1 CY1123826 T1 CY 1123826T1
- Authority
- CY
- Cyprus
- Prior art keywords
- carbonitrile
- isoquinoline
- dioxide
- methyl
- thiadiazinan
- Prior art date
Links
- HJHXYSBRTVFEDD-UHFFFAOYSA-N isoquinoline-1-carbonitrile Chemical compound C1=CC=C2C(C#N)=NC=CC2=C1 HJHXYSBRTVFEDD-UHFFFAOYSA-N 0.000 title abstract 2
- 229940083324 Selective androgen receptor modulator Drugs 0.000 abstract 2
- 239000000849 selective androgen receptor modulator Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461993693P | 2014-05-15 | 2014-05-15 | |
| US201562138037P | 2015-03-25 | 2015-03-25 | |
| PCT/IB2015/053194 WO2015173684A1 (en) | 2014-05-15 | 2015-05-01 | Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123826T1 true CY1123826T1 (el) | 2022-05-27 |
Family
ID=53276206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100138T CY1123826T1 (el) | 2014-05-15 | 2021-02-18 | Κρυσταλλικη μορφη 6 - [(4r) -4-μεθυλο-1,2-διοξειδο-1,2,6-θειαδιαζιναν-2-υλ]ισοκινολινο-1-καρβονιτριλιου |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9920043B2 (enExample) |
| EP (1) | EP3143019B1 (enExample) |
| JP (1) | JP6523782B2 (enExample) |
| KR (1) | KR101817889B1 (enExample) |
| CN (1) | CN106459025B (enExample) |
| AU (1) | AU2015260906B2 (enExample) |
| CA (1) | CA2891398C (enExample) |
| CY (1) | CY1123826T1 (enExample) |
| DK (1) | DK3143019T3 (enExample) |
| ES (1) | ES2845639T3 (enExample) |
| HU (1) | HUE052692T2 (enExample) |
| IL (1) | IL248918A0 (enExample) |
| MX (1) | MX371014B (enExample) |
| PL (1) | PL3143019T3 (enExample) |
| PT (1) | PT3143019T (enExample) |
| RU (1) | RU2698194C2 (enExample) |
| SG (1) | SG11201608320QA (enExample) |
| SI (1) | SI3143019T1 (enExample) |
| TW (1) | TWI553007B (enExample) |
| WO (1) | WO2015173684A1 (enExample) |
| ZA (1) | ZA201606796B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2950390C (en) * | 2014-05-30 | 2020-09-22 | Pfizer Inc. | Carbonitrile derivatives as selective androgen receptor modulators |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0089139A2 (en) | 1982-03-16 | 1983-09-21 | Beecham Group Plc | Antibiotics, their preparation and use |
| US4489075A (en) * | 1982-05-15 | 1984-12-18 | Pfizer Inc. | Cyclic sulfonamidoalkyl substituted 4-piperidinoquinazoline cardiac stimulants |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| EP1636167A2 (en) | 2003-06-10 | 2006-03-22 | SmithKline Beecham Corporation | 1-aminonaphthalenes as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors |
| US7816372B2 (en) * | 2003-08-22 | 2010-10-19 | Ligand Pharmaceuticals Incorporated | 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds |
| MX2010006972A (es) * | 2007-12-21 | 2010-08-26 | Ligand Pharm Inc | Moduladores selectivos de receptores de andrógenos (sarm) y usos de los mismos. |
| MY176727A (en) * | 2012-12-03 | 2020-08-20 | Pfizer | Selective androgen receptor modulators |
-
2015
- 2015-05-01 SI SI201531479T patent/SI3143019T1/sl unknown
- 2015-05-01 HU HUE15726337A patent/HUE052692T2/hu unknown
- 2015-05-01 ES ES15726337T patent/ES2845639T3/es active Active
- 2015-05-01 KR KR1020167031696A patent/KR101817889B1/ko not_active Expired - Fee Related
- 2015-05-01 PL PL15726337.7T patent/PL3143019T3/pl unknown
- 2015-05-01 WO PCT/IB2015/053194 patent/WO2015173684A1/en not_active Ceased
- 2015-05-01 EP EP15726337.7A patent/EP3143019B1/en not_active Not-in-force
- 2015-05-01 US US15/310,570 patent/US9920043B2/en active Active
- 2015-05-01 PT PT157263377T patent/PT3143019T/pt unknown
- 2015-05-01 RU RU2016144671A patent/RU2698194C2/ru active
- 2015-05-01 DK DK15726337.7T patent/DK3143019T3/da active
- 2015-05-01 SG SG11201608320QA patent/SG11201608320QA/en unknown
- 2015-05-01 MX MX2016014999A patent/MX371014B/es active IP Right Grant
- 2015-05-01 CN CN201580025357.8A patent/CN106459025B/zh not_active Expired - Fee Related
- 2015-05-01 AU AU2015260906A patent/AU2015260906B2/en not_active Ceased
- 2015-05-13 JP JP2015097829A patent/JP6523782B2/ja not_active Expired - Fee Related
- 2015-05-14 CA CA2891398A patent/CA2891398C/en active Active
- 2015-05-14 TW TW104115438A patent/TWI553007B/zh not_active IP Right Cessation
-
2016
- 2016-10-03 ZA ZA2016/06796A patent/ZA201606796B/en unknown
- 2016-11-13 IL IL248918A patent/IL248918A0/en unknown
-
2021
- 2021-02-18 CY CY20211100138T patent/CY1123826T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI553007B (zh) | 2016-10-11 |
| RU2016144671A (ru) | 2018-06-15 |
| MX2016014999A (es) | 2017-04-11 |
| JP2015218166A (ja) | 2015-12-07 |
| ES2845639T3 (es) | 2021-07-27 |
| EP3143019A1 (en) | 2017-03-22 |
| US9920043B2 (en) | 2018-03-20 |
| TW201546069A (zh) | 2015-12-16 |
| PL3143019T3 (pl) | 2021-03-22 |
| EP3143019B1 (en) | 2020-12-16 |
| PT3143019T (pt) | 2021-01-28 |
| AU2015260906B2 (en) | 2017-08-31 |
| MX371014B (es) | 2020-01-10 |
| ZA201606796B (en) | 2018-04-25 |
| CN106459025A (zh) | 2017-02-22 |
| SI3143019T1 (sl) | 2021-03-31 |
| HUE052692T2 (hu) | 2021-05-28 |
| WO2015173684A1 (en) | 2015-11-19 |
| SG11201608320QA (en) | 2016-11-29 |
| AU2015260906A1 (en) | 2016-10-20 |
| CA2891398A1 (en) | 2015-11-15 |
| DK3143019T3 (da) | 2021-01-04 |
| KR20160144478A (ko) | 2016-12-16 |
| JP6523782B2 (ja) | 2019-06-05 |
| RU2016144671A3 (enExample) | 2018-06-15 |
| CN106459025B (zh) | 2019-05-28 |
| CA2891398C (en) | 2019-09-24 |
| US20170073338A1 (en) | 2017-03-16 |
| RU2698194C2 (ru) | 2019-08-23 |
| IL248918A0 (en) | 2017-01-31 |
| KR101817889B1 (ko) | 2018-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3215133T3 (pl) | Sposoby i kompozycje związane z zastosowaniem związków powierzchniowo czynnych o niskiej hlb do wytwarzania syntetycznych nanonośników zawierających rapalog | |
| IL248519A0 (en) | Bioceramic compositions and biomodulatory uses thereof | |
| HUE056583T2 (hu) | 6-Karboxi-2-(3,5-diklórfenil)-benzoxazol kristályos szilárd formái | |
| EA201691272A1 (ru) | Тетрагидропиридопиразины в качестве модуляторов gpr6 | |
| MX391539B (es) | Proceso de compuesto antifungico. | |
| DK3102555T3 (da) | Sammensætninger af forbindelser og anvendelser deraf | |
| DK3390354T3 (da) | Fremgangsmåde til tilvejebringelse af carbondioxid til syntese af urea | |
| HUE058257T2 (hu) | Eljárások oxatiazin-jellegû vegyületek elõállítására | |
| DK3307675T3 (da) | Multi-tryk-fremgangsmåde til fremstilling af ammoniak | |
| HUE050974T2 (hu) | Eljárás pirimidinszulfamid-származékok elõállítására | |
| CL2017000152A1 (es) | Derivados de isoindolinona | |
| SI3160948T1 (sl) | Amidi benzoksazinona, kot modulatorji receptorja mineralokortikoida | |
| BR112016019510A2 (pt) | esterilização e filtração de composições de peptídeos | |
| HUE049170T2 (hu) | Eljárás szubsztituált cikloszerinek elõállítására | |
| CY1124164T1 (el) | Καινοτομος παρασκευη και κρυσταλλωση της ιοσιμενολης | |
| CL2017000151A1 (es) | Derivados de piridona | |
| SG11201606443WA (en) | Synthesis of framework modified zsm-48 crystals | |
| DK3164116T3 (da) | Brusesammensætninger indeholdende co-krystaller af syredelen | |
| CY1123826T1 (el) | Κρυσταλλικη μορφη 6 - [(4r) -4-μεθυλο-1,2-διοξειδο-1,2,6-θειαδιαζιναν-2-υλ]ισοκινολινο-1-καρβονιτριλιου | |
| HUE051196T2 (hu) | Nitrogénmustár-származékok elõállítására szolgáló eljárás | |
| HRP20181112T1 (hr) | Supstituirani derivati azaspiro(4,5)dekana | |
| EP3171860C0 (en) | SOLID ORAL FORMULATION OF FENRETINIDE | |
| DK3190088T3 (da) | Fremgangsmåde til syntese af ammoniak | |
| DK3541784T5 (da) | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | |
| BR112017008594A2 (pt) | derivados de 2-(1,2,4-triazol-3-ilsulfanil)-n-1,3,4-tiadiazol-2-il acetamida que são úteis para o tratamento de diabetes inter alia |